JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial

BACKGROUND: Inflammation signaled by Janus kinases (JAKs) promotes progression of diabetic kidney disease (DKD). Baricitinib is an oral, reversible, selective inhibitor of JAK1 and JAK2. This study tested the efficacy of baricitinib versus placebo on albuminuria in adults with Type 2 diabetes at hig...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Nephrol Dial Transplant
Main Authors: Tuttle, Katherine R, Brosius, Frank C, Adler, Sharon G, Kretzler, Matthias, Mehta, Ravindra L, Tumlin, James A, Tanaka, Yoshiya, Haneda, Masakazu, Liu, Jiajun, Silk, Maria E, Cardillo, Tracy E, Duffin, Kevin L, Haas, Joseph V, Macias, William L, Nunes, Fabio P, Janes, Jonathan M
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2018
Assuntos:
ORIGINAL ARTICLES
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6212720/
https://ncbi.nlm.nih.gov/pubmed/29481660
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ndt/gfx377
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares